# MINDACT (NCT00433589)

> Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00433589
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Conditions: Breast Cancer
- Interventions: anthracycline-based; docetaxel and capecitabine; tamoxifen; Letrozole
- Enrollment: 6600
- Primary outcome: Distant metastasis-free survival at 5 years
- Primary outcome: Disease-free survival (DFS)
- Primary outcome: DFS

## Commentary we found

- YouTube: 22
- Podcasts: 11
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=mindact-nct00433589

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00433589", "email": "<work email>"}; the inbox owner confirms by the emailed link.